More importantly, nasal BPC-157 lacks human clinical data
Reported side effects in human anecdotal use are generally mild and may include: Mild nausea, particularly with oral administration Redness, itching, or irritation at the injection site Temporary dizziness or mild headache Changes in appetite or weight A significant theoretical concern revolves around its pro-angiogenic properties
Mylan: Method of Treatment Claims Must Be Aligned with Label, accessed February 2, 2026, Skinny Labeling: Origins, Evolution, and Key Decisions | PharmExec, accessed February 2, 2026, Skinny Labels for Generic Drugs Under Hatch-Waxman | Congress.gov, accessed February 2, 2026, Generic Drugs and the Struggle to Compete: The Role of Skinny Labels PMC NIH, accessed February 2, 2026, Skinny Facts May Limit Supreme Courts Decision in Skinny Label Generic Drug Approval Case McGuireWoods, accessed February 2, 2026, Amarin v
Epithalon is a synthetic version of Epithalamin, a natural polypeptide naturally produced in the pineal gland of the brain
Retatrutide has reported a larger average weight-loss effect than tirzepatide (the active ingredient in Mounjaro and Zepbound) in their respective trials roughly 28% versus roughly 2122% over similar timeframes largely because retatrutide adds a glucagon receptor on top of the GIP and GLP-1 targets tirzepatide already uses
